Login to Your Account


LONDON – Newco Valo Therapeutics Ltd. has spun out of Helsinki University, Finland, with €3 million of a first tranche of seed funding to commercialize next-generation peptide-coated oncolytic viruses that promote a specific antitumor immune activation.

As the biopharma industry paused on Rare Disease Day to assess its progress and consider the plight of patients still waiting for therapeutic options, two players at opposite ends of the U.S. took the field in DMD.

To say that the discovery leading to Aobiome LLC's approach to treat disease by targeting the microbiome came via an unconventional method is an understatement.

More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: